CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris® (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.
European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation | Alexion Pharmaceuticals, Inc
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.